Driehaus Capital Management’s TG Therapeutics TGTX Stock Holding History

Driehaus Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-807,833	Closed	-$29.1M	–	504
2025 Q2	$29.1M	Buy	807,833 +33,177	+4%	+$1.24M	0.23%	140
2025 Q1	$30.5M	Buy	+774,656	New	+$26.1M	0.29%	109
2024 Q1	–	Sell	-185,441	Closed	-$3.17M	–	447
2023 Q4	$3.17M	Buy	+185,441	New	+$2.16M	0.04%	282
2023 Q3	–	Sell	-363,831	Closed	-$9.04M	–	446
2023 Q2	$9.04M	Sell	363,831 -483,913	-57%	-$12.5M	0.11%	226
2023 Q1	$12.8M	Buy	+847,744	New	+$12.9M	0.18%	187
2015 Q2	–	Sell	-42,521	Closed	-$658K	–	582
2015 Q1	$658K	Buy	42,521 +13,821	+48%	+$209K	0.02%	441
2014 Q4	$455K	Buy	+28,700	New	+$374K	0.02%	444

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Driehaus Capital Management's TGTX Position: Q3 2025 in Review

Driehaus Capital Management sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 807,833 shares — an estimated $29.1M sold.

Driehaus Capital Management first reported a position in TGTX in Q4 2014 and held it in 7 quarters. The position peaked at $30.5M in Q1 2025. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

Driehaus Capital Management reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
Driehaus Capital Management sold 807,833 TG Therapeutics shares in Q3 2025, an estimated $29.1M.
Driehaus Capital Management first reported a position in TG Therapeutics in Q4 2014 and held it in 7 quarters.
Driehaus Capital Management's TG Therapeutics position peaked at $30.5M in Q1 2025.
354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Driehaus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.